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ABSTRACT
Introduction: Varicella zoster virus (VZV) causes
varicella (chicken pox) and herpes zoster (shingles).
Worldwide, these diseases are associated with
significant morbidity. Most of the epidemiological data
on VZV come from high income countries. There are
few data on VZV in Africa, where tropical climates and
high HIV/AIDS prevalence rates are expected to impact
the epidemiology of VZV. Safe and effective vaccinations
for both varicella and herpes zoster exist, but are not
routinely used in Africa. There are very few data
available on VZV disease burden in Africa to guide the
introduction of these vaccines on the continent. Our aim
is to conduct a systematic review of the VZV-associated
morbidity and mortality in Africa, which will provide
critical information that could be used to develop
vaccination policies against these diseases in Africa.
Methods and analysis: Electronic databases will be
searched and all studies published after 1974 that meet
predefined criteria will be assessed. The primary
outcomes for the study are VZV incidence/prevalence,
hospitalisation rates and total death rates. The
secondary outcome for this study is the proportion of
VZV hospitalisations and/or deaths associated with HIV/
AIDS. Two reviewers will screen the titles and abstracts,
and then independently review the full texts, to
determine if studies are eligible for inclusion. A risk of
bias and quality assessment tool will be used to score
all included studies. Following standardised data
extraction, a trend analysis using R-programming
software will be conducted to investigate the trend of
VZV. Depending on the characteristics of included
studies, subgroup analyses will be performed. This
review will be reported according to the Preferred
Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines.
Ethics and dissemination: As this is a protocol for a
systematic review, which will use already published
data, no ethics approval is required. Findings will be
disseminated in peer-reviewed journals.
Trial registration number: CRD42015026144.
BACKGROUND
Varicella zoster virus (VZV), belonging to
the Herpesviridae family, causes varicella
(chicken pox) and, later, through endogenous
reactivation, herpes zoster (shingles). Both
diseases occur worldwide, and while their
mortality is generally low, these diseases have a
high morbidity, and place a large burden on
healthcare systems and society.1 There is no
synthesised literature on the burden of vari-
cella and herpes zoster in Africa.
Varicella is characterised by a vesicular rash
and fever, and in children is usually a mild,
self-limiting illness. Complications, however,
do occur, particularly in infants, pregnant
women and other adults, and in immuno-
compromised individuals, including those
with HIV.1 2 Globally, on average, 4.2 million
cases of severe varicella result in hospitalisa-
tion or death each year.2 Prior to widespread
usage of vaccines against varicella in temper-
ate high income countries, 13–16 cases of
varicella per 1000 population occurred annu-
ally, mostly affecting children aged 1–9 years.1
In these settings, >90% of the population
becomes infected with VZV before adoles-
cence.2 In tropical regions, primary infection
of varicella tends to occur at a later stage,
Strengths and limitations of this study
▪ This is the first time data on Varicella zoster
virus (VZV) in Africa have been collated in a sys-
tematic review.
▪ The data reporting adheres to the Preferred
Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) guidelines.
▪ Publication bias - only published studies will be
included in the review. Data from national health
departments will not be used as there is no stan-
dardised data collection for VZV across the
continent.
▪ If the majority of the data are collected from
healthcare facilities, cases that do not have
access to these facilities will be missed, making
the study further underestimate the burden of
VZV in Africa.
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resulting in a larger population of susceptible adults and
potentially a higher proportion of severe cases.2 3
After an episode of varicella, VZV remains dormant in
the dorsal root ganglia, and reactivation results in zoster,
a painful vesicular rash, usually conﬁned to one derma-
tome.4 The incidence of herpes zoster increases with
increasing age, especially after 50 years of life. For
example, half of all 85-year-old individuals have experi-
enced an episode of herpes zoster.2 Decreasing cell-
mediated immunity due to, for example, HIV infection,
cancer, diabetes mellitus or immunosuppressive treat-
ment, also increases the risk of zoster.2 Compared with
HIV-negative individuals, persons with HIV have a 12–
17-fold greater risk of developing zoster. In areas with a
high HIV prevalence, zoster has an 85–95% positive pre-
dictive value for underlying HIV infection.5 The most
common complications of zoster are post-herpetic neur-
algia and ocular complications.6 About 3% of zoster
patients are hospitalised.7 There are few data on zoster
mortality, but studies from Europe and North America
suggest that it is around 0.25 per 1 million population,
mostly in the elderly.7 Timely vaccination against zoster
may prevent such deaths.
Effective vaccines exist for both varicella and zoster,
and are used widely in high-income countries, with con-
siderable beneﬁts.2 In 1998, the WHO recommended
the introduction of routine childhood vaccination
against VZV in settings where the disease has signiﬁcant
negative socioeconomic impact.8 But vaccines against
VZV are rarely used on the African continent.
Introducing these vaccines would be in agreement with
the Global Immunisation Vision and Strategy (GIVS) of
the WHO and UNICEF. The GIVS aims to widely intro-
duce a range of newly available vaccines and immunise
more people against as many vaccine-preventable dis-
eases as possible.9 Achieving this aim would promote
health, but would also improve equitable access to
immunisation.9
Decisions to introduce vaccines against varicella and
zoster in most African countries need to be guided by
evidence-based data on the epidemiology and socio-
economic impacts of the diseases. To the best of our
knowledge, at present, there are no synthesised
VZV-associated epidemiological data in Africa.
Furthermore, cost-effectiveness studies of introducing
the vaccines against varicella and shingles are lacking in
Africa.
The African continent has several risk factors that
could result in an increased burden of VZV disease.
First, for varicella, there is a high prevalence of HIV/
AIDS and, in tropical countries, primary infections
occur at an older age, both of which increase the
chance of developing severe varicella. Second, for zoster,
there is an increasing ageing population, high HIV/
AIDS burden and diabetes prevalence is growing.10 11
Third, for both varicella and zoster, weak and over-
stretched healthcare systems in Africa cannot efﬁciently
manage complications of these diseases.
Rationale
Globally, major variations in the epidemiology of
VZV-associated disease exist. As such, some countries
have adopted universal childhood vaccination against
VZV while others recommend targeted vaccination of
high-risk populations only.1 In Africa, there is no col-
lated evidence on the burden of varicella and zoster that
could be used to inform decisions around vaccine intro-
duction for these diseases. Furthermore, the impact of
the HIV/AIDS pandemic on the epidemiology of VZV is
also not clear, and any decisions around introduction of




This study attempts to describe the epidemiology of VZV
in Africa, taking into account the clinical diseases of
varicella and zoster.
Primary objectives
▸ To summarise the available data on the varicella-
associated morbidity and mortality in Africa
▸ To summarise the available data on the herpes zoster-
associated morbidity and mortality in Africa.
Secondary objective
To assess the impact of HIV/AIDS on the epidemiology
of varicella and herpes zoster in Africa.
Eligibility criteria
Types of participants
Studies on the epidemiology of VZV, in adults and chil-
dren, from any country in Africa, will be included in the
review.
Case definition
Included studies must have clearly stated the case deﬁn-
ition for varicella. The case deﬁnition for varicella, as
deﬁned by the Centres for Disease Control and
Prevention (CDC), will be used for morbidity and mor-
tality estimation:12
Clinical description: An acute illness with diffuse
maculopapulovesicular rash, without other apparent
cause.
Laboratory criteria: Isolation of varicella virus from a
clinical specimen, or varicella antigen detected by direct
ﬂuorescent antibody test, or varicella-speciﬁc nucleic
acid detected by PCR, or signiﬁcant rise in serum anti-
varicella IgG antibody level by any standard serologic
assay.
The case deﬁnition of herpes zoster uses only the
clinical description (painful maculopapulovesicular
rash, usually conﬁned to a dermatome), as it has been
shown to be distinctive enough to make an accurate clin-
ical diagnosis.13
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Inclusion criteria
Studies will be included if they are conducted in Africa,
measure or report any of the primary outcomes listed
below and have a case deﬁnition for varicella or herpes
zoster.
Exclusion criteria
Studies will be excluded from this review if they are not
conducted in Africa, do not measure any of the primary
outcomes listed below and have not stated a case deﬁni-
tion of varicella or herpes zoster.
Outcomes
Primary outcomes
▸ Incidence or prevalence of varicella or herpes zoster
▸ Hospitalisation rates associated with varicella or
herpes zoster
▸ Total deaths associated with varicella or herpes zoster.
Secondary outcomes
Proportion of varicella or herpes zoster hospitalisations
and/or deaths associated with HIV/AIDS.
Type of studies
Case-series, cross-sectional, cohort and intervention
studies will be included. All studies published from
January 1974 to September 2015 will be included
without language restrictions. First, Google translator
software will be used to enable preliminary screening of
non-English records by titles or abstracts that appear
likely to be included. If the article still appears likely for
inclusion, we will then seek translation support from a
native speaker of the language used in the article, within
our network of collaborators. If unsuccessful with this
option, we will seek professional translation services.
Search strategy
The literature search strategy will use both text words
and Medical Subject Heading (MeSH) terms and will
include the following: VZV, human herpes virus 3, vari-
cella, chicken pox, herpes zoster and shingles, as well as
prevalence, incidence, epidemiology, burden, hospital-
isation or hospitalization, and mortality and case-fatality
rates. These terms will be adapted for each database and
then combined with a relevant ﬁlter to select out studies
from the African continent only. An example of the
PubMed search strategy is shown in table 1.
Electronic databases
The following electronic databases will be searched:
PubMed, Scopus, Africa-wide, Embase, WHOLIS,
PDQ-Evidence, CENTRAL, CINAHL and Web of
Science.
Selection of eligible studies
The ﬁrst and the second authors (HSH and LHA) will
screen the search outputs using titles and abstracts. In
addition, study setting, study design, methods as well as
study outcomes will be evaluated. The two authors will
then independently read through the full text of all
potentially eligible studies to assess if inclusion criteria
are met. Discrepancies in the list of included studies
between the two authors will be resolved through discus-
sion and consensus, with the assistance of the last author
(BMK).
Table 1 PubMed search strategy
Query
number Search terms
#1 ‘Herpesvirus 3, Human’[Mesh] OR ‘Varicella
zoster’
#2 ‘Chickenpox’[Mesh] OR varicella OR
‘Herpes Zoster’[Mesh]
#3 #1 OR #2
#4 epidemiology OR prevalence OR incidence
OR burden
#5 hospitalisation OR hospitalization OR
mortality OR ‘case-fatality rate’
#6 #4 OR #5
#7 #3 AND #6
#8 ‘Africa’[Mesh]
#9 (Algeria) OR (Angola) OR (Benin OR
Dahomey) OR (Botswana) OR (‘Burkina
Faso’ OR ‘Republic of Upper Volta’) OR
(Burundi) OR (Cameroon) OR (‘Canary
Islands’) OR (‘Cape Verde’) OR (‘Central
African Republic’) OR (Chad) OR
(Comoros) OR (Congo) OR ((‘Democratic
Republic of Congo’) OR (Zaire)) OR
(Djibouti) OR (Egypt) OR (‘Equatorial
Guinea’) OR (Eritrea) OR (Ethiopia) OR
(Gabon) OR (Gambia) OR (Ghana) OR
(Guinea) OR (‘Guinea Bissau’) OR (‘Ivory
Coast’ OR ‘Cote d’Ivoire’) OR (Kenya) OR
(Lesotho) OR (Liberia) OR ((Libya) OR
(Libia) OR ( Jamahiriya) OR ( Jamahiryia))
OR (Madagascar) OR (Malawi) OR (Mali)
OR (Mauritania) OR (Mauritius) OR
(Morocco) OR ((Mozambique) OR
(Moçambique)) OR ((Namibia) OR (‘South
West Africa’)) OR (Niger) OR (Nigeria) OR
(Reunion) OR (Rwanda) OR (‘Sao Tome’)
OR (Senegal) OR (Seychelles) OR (‘Sierra
Leone’) OR (Somalia) OR (‘South Africa’)
OR (‘St Helena’) OR (‘South Sudan’) OR
(Sudan) OR (Swaziland) OR (Tanzania) OR
(Togo) OR (Tunisia) OR (Uganda) OR
(‘Western Sahara’) OR (Zambia) OR
(Zimbabwe OR Rhodesia) OR (South* AND
Africa*) OR (West* AND Africa*) OR (East*
AND Africa*) OR (North* AND Africa*) OR
(Central* AND Africa*) OR (Sub-Saharan
Africa*) OR (Subsaharan Africa*) OR
(Africa*) NOT ((Guinea Pig*) OR
((Aspergillus Niger) OR ‘Aspergillus Niger’))
#10 #8 OR #9
#11 #7 AND #10
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Data collection process
Data will be independently extracted from the included
studies by two reviewers, and recorded on a predesigned
form. If need be, corresponding authors for the
included studies will be contacted where the data are
unclear. The following data will be extracted from the
included studies:
▸ Study characteristics: year of the study publication,
study design and objectives of the study
▸ Study population: country, community or healthcare
facility based and the source of the denominator
▸ Case deﬁnition: laboratory methods and clinical case
deﬁnitions
▸ Incidence or prevalence of VZV
▸ Mortality and hospitalisation rates associated with the
VZV
▸ Prevalence of complications of VZV not requiring
hospitalisation, for example, postherpetic neuralgia
▸ Characteristics of VZV cases: age, gender, HIV status,
access to acyclovir or other antiviral treatment, vaccin-
ation status.
Risk of bias assessment and strength of the cumulative
results for included studies
We will adapt the risk of bias and quality assessment tool
developed by Hoy et al14 and modiﬁed by others for
evaluating prevalence studies.15 This scoring tool, which
will be used on all the included studies, examines the
internal and external validity by taking into account
study design, methodology and the presence of bias.
From the several quality assessment tools available, we
chose to adapt the tool developed by Hoy et al14 for the
following reasons: (1) it is speciﬁcally designed for
prevalence studies; (2) it is an improved tool developed
after a rigorous published process, including a review of
the limitations of the existing tools; (3) detailed criteria
to use the tool are provided, making it easier to use; (4)
it has a high inter-rater agreement; and (5) it is robust
in application and, for example, can be used alongside
the latest tool developed by the Joanna Briggs Institute
( JBI) and the Cochrane Collaboration.16
Two authors (HSH and LHA) will independently
score the risk of bias using the tool and a κ agreement
will be calculated. This risk of bias and quality assess-
ment tool is given in table 2. The strength of the cumu-
lative evidence will be based on the average score
obtained following the criteria described in table 2. An
average score of 1, 2, 3 and 4 points would imply the
cumulative evidence is weak, average, strong and very
strong, respectively.
This review will not include unpublished reports, and
therefore is at risk of publication bias. As there is no
standardised data collection for VZV across the contin-
ent, data from national health departments will not be
used. The practical difﬁculties of collecting this set of
data are a further reason for not collecting it, and this is
a limitation of our study. Furthermore, if data are col-
lected from health systems, they are automatically
limited to medically attended cases and may miss milder
cases or persons who have less access to healthcare ser-
vices, which occurs commonly in Africa. We, therefore,
acknowledge that our study is likely to underestimate the
burden of the VZV-associated disease in Africa.
Data synthesis
The results from the included studies will be reported as
incidence and/or prevalence of varicella or herpes
zoster, as well as hospitalisation and death rates, using
mean and SDs. A trend analysis will be conducted to
investigate the trend of varicella or herpes zoster burden
in Africa over time. R-programming software will be
used to perform the statistical calculations.
If the studies included have a high heterogeneity (this
will be examined by χ2 test of homogeneity and





1. Was the study’’s target population a close representation of the national population in relation to relevant
variables?
(1 point)
2. Was the sampling frame a true or close representation of the target population? (1 point)
3. Was some form of random selection used to select the sample, or was a census undertaken? (1 point)
4. Was the likelihood of non-response bias minimal? (1 point)
Total (4 points)
Internal validity
1. Were data collected directly from the participants (as opposed to a proxy)? (1 point)
2. Was an acceptable case definition used in the study? (1 point)
3. Was the study instrument that measured the parameter of interest shown to have validity and reliability? (1 point)
4. Was the same mode of data collection used for all participants? (1 point)
5. Was the length of the shortest prevalence period for the parameter of interest appropriate? (1 point)
6. Were the numerator(s) and denominator(s) for the parameter of interest appropriate? (1 point)
Total (6 points)
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quantiﬁed using the I2 statistic) the ﬁndings will be pre-
sented in a narrative form that describes regions or
countries with similar epidemiology of the disease.
Subgroup analysis
The ﬁndings from each country will be reported separ-
ately as part of a subgroup analysis. In addition, further
subgroup analyses will be conducted, where sufﬁcient
data exist, based on whether the study was conducted in
the community or in a healthcare centre, the income
status of the countries as classiﬁed by the World Bank,
national background HIV/AIDS prevalence rates, case
deﬁnition criteria and geographical setting or popula-
tion density (urban vs rural settings).17
Sensitivity analysis
For the meta-analysed data, a sensitivity analysis will be
performed to determine if the exclusion of highly
biased studies (based on the risk of bias assessment) will
change the ﬁndings of the meta-analysis.
Data management
Data management will be the responsibility of the ﬁrst
author (HSH) in consultation with the last author
(BMK). An electronic parent folder with the name of
this study will be created. Subsequently, subfolders will
be created that contain details of different tasks com-
pleted, such as all records retrieved, records included
and excluded, risk of bias assessment results, analyses
and full systematic review manuscript drafts. Two
back-ups of the parent folder will be created, and stored
on a memory stick as well as in a different computer.
Reporting of the review
The ﬁndings of this systematic review will be reported
according to the Preferred Reporting Items for
Systematic reviews and Meta-Analyses (PRISMA) guide-
lines, and will include a summary ﬂow diagram on how
articles were selected, as well as a list of excluded studies
and the reasons for exclusion. Narrative reporting will
be used to describe any qualitative data from the studies.
DISCUSSION
While there is a relatively large amount of epidemio-
logical data on VZV in high income countries, there are
only limited data from African countries. As there are
major differences in the epidemiology of VZV-associated
diseases between high, and low or middle income coun-
tries (LMIC’s), data from high income countries cannot
be extrapolated to LMIC’s. A review from Latin America,
for instance, found a much higher incidence of varicella
compared with that in the USA, while a review from Asia
found that a signiﬁcant proportion of individuals are
infected with varicella for the ﬁrst time only after child-
hood.3 18 Our proposed systematic review will generate
useful data on the burden of VZV in Africa, taking into
account the high burden of HIV/AIDS. These results
could be used as the ﬁrst step towards developing vaccin-
ation control plans for varicella and zoster on the
continent.
If the VZV-associated disease burden in Africa is found
to be high, follow-up studies would be needed to deter-
mine the cost-effectiveness and feasibility of vaccination
in this setting. It has been suggested that universal
infant immunisation against varicella would not be pos-
sible in LMIC’s, and that high-risk groups, such as
immunocompromised individuals or healthcare workers,
should be targeted for vaccination instead.1 But here
again, more epidemiological data would be needed to
inform such decisions. Furthermore, if the rates of VZV
complications and/or hospitalisation were found to be
high, it would provide strong evidence for wider accessi-
bility of drugs such as acyclovir or those needed to treat
post-herpetic neuralgia on the continent.
One of our study limitations is that only severe cases
of VZV-associated cases are hospitalised or reported and
in Africa, poor access to healthcare services is prevalent.
Therefore, we are very likely to underestimate the
burden of these diseases in our review. As such, even if
our study ﬁnds the VZV-associated disease burden is low
on the continent, we suggest that this review needs to be
continuously updated. In addition, access to healthcare
should improve over time and more data on
VZV-associated cases will become available. Updating the
review is also important as the epidemiology of many dis-
eases, including varicella and zoster, will continue to
change over time, as demographic changes occur and
urbanisation increases. It is also important that the back-
ground epidemiology of vaccine-preventable diseases on
the continent is known and updated regularly, as part of
a general surveillance programme and for the review of
vaccination policies.
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